AbCellera Biologics Inc. (ABCL): Price and Financial Metrics
ABCL Price/Volume Stats
| Current price | $3.63 | 52-week high | $8.05 |
| Prev. close | $3.90 | 52-week low | $3.62 |
| Day low | $3.62 | Volume | 1,829,900 |
| Day high | $3.88 | Avg. volume | 1,372,955 |
| 50-day MA | $4.61 | Dividend yield | N/A |
| 200-day MA | $5.13 | Market Cap | 1.06B |
ABCL Stock Price Chart Interactive Chart >
AbCellera Biologics Inc. (ABCL) Company Bio
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics. It was founded in 2012 and headquartered in Vancouver, British Columbia.
Latest ABCL News From Around the Web
Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024VANCOUVER, British Columbia, December 20, 2023--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). |
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
16 Best Penny Stocks To Buy For 2024In this article, we will take a detailed look at the 16 Best Penny Stocks To Buy For 2024. For a quick overview of such stocks, read our article 5 Best Penny Stocks To Buy For 2024. The stock market’s optimism wave recently saw a break after latest data showed that the US labor market remains resilient despite […] |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
AbCellera Biologics Insiders Added US$2.47m Of Stock To Their HoldingsOver the last year, a good number of insiders have significantly increased their holdings in AbCellera Biologics Inc... |
ABCL Price Returns
| 1-mo | -19.15% |
| 3-mo | -31.77% |
| 6-mo | -7.16% |
| 1-year | -45.33% |
| 3-year | -87.69% |
| 5-year | N/A |
| YTD | -36.43% |
| 2023 | -43.63% |
| 2022 | -29.16% |
| 2021 | -64.46% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...